Cagrilintide Peptide Profile

Cagrilintide Peptide Profile and Dosing Protocol

Cagrilintide is a long‑acting analogue of the hormone amylin, designed to regulate appetite by slowing gastric emptying and promoting satiety, with potential therapeutic use for obesity and type 2 diabetes management (Wikipedia, 2025). It is administered by once‑weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm (ensayosclinicos.es, 2025). In clinical studies, cagrilintide has been evaluated across a range of weekly doses (0.3–4.5 mg), with greater weight loss observed at higher doses (Lau et al., 2021; Sochob.cl, 2021).

Dose escalation is a common protocol in research settings: starting with a low dose and titrating up over several weeks to a target maintenance dose. For example, phase 3 trial protocols often begin at ~0.25–0.3 mg weekly and escalate in defined increments every 2–4 weeks until reaching a maintenance dose of 2.4 mg weekly, which may be continued based on clinical response (Peptides.org, 2024; PepDose, 2025). When combined with semaglutide in the CagriSema regimen, both agents are escalated concomitantly to 2.4 mg weekly each (PatchMD, 2025). Clinical monitoring includes tolerance, appetite suppression, and adverse effects.

References

Peptides.org. (2024). Cagrilintide dosage guideline.
PepDose. (2025). Cagrilintide dosage chart.
ensayosclinicos.es. (2025). Cagrilintide application in therapy.
Sochob.cl. (2021). Cagrilintide weight loss study.
Wikipedia. (2025). Cagrilintide.
PatchMD. (2025). CagriSema dosing.

Dosing Chart (Weekly Escalation)